Regulatory Roundup: FDA Introduces Safe Use Initiative, More... - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Regulatory Roundup: FDA Introduces Safe Use Initiative, More...

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration introduced the Safe Use Initiative, a program designed to reduce the likelihood of preventable harm from medication use. The agency said in a press release that millions of people are harmed every year from inappropriate medication use, and that many injuries occur as a result of incomplete access to information about a drug, patient, or patient’s condition. FDA intends to collaborate with healthcare professionals and other stakeholders to identify drugs and drug classes that are linked to preventable harm. The agency also made public new draft guidance titled Dosage Delivery Devices for OTC Liquid Drug Products for companies that manufacture, market, or distribute over-the-counter liquid medications packaged with dosage-delivery devices such as calibrated cups, droppers, syringes, and spoons.

FDA Comissioner Margaret Hamburg sent a letter on Nov. 10, 2009, to America’s healthcare professionals that acknowledged their efforts during the 2009 influenza A (H1N1) outbreak and provided information on the safety of the H1N1 vaccines. The letter offered information designed to aid physicians in their discussions with patients about the manufacture, monitoring, and safety of the vaccine.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
13%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
23%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
NSF, Microsoft Team in Cloud Computing
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here